NCT06352528View on ClinicalTrials.gov

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 29, 2024

Primary Completion Date

September 16, 2025

Study Completion Date

September 16, 2025

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

Repotrectinib

Specified dose on specified days

Trial Locations (3)

78215

The Texas Liver Institute, Inc., San Antonio

33014-2811

Panax Clinical Research, Miami Lakes

32809-3017

Orlando Clinical Research Center, Orlando

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06352528 - A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment | Biotech Hunter | Biotech Hunter